Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “buy” rating reiterated by analysts at Wells Fargo in a report issued on Wednesday.

A number of other analysts have also recently commented on the company. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. BMO Capital Markets restated a “market perform” rating and issued a $19.00 price objective (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Needham & Company LLC restated a “buy” rating and issued a $24.00 price objective (up from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $21.33.

How to Become a New Pot Stock Millionaire

AMPH stock opened at $19.12 on Wednesday. The company has a current ratio of 2.79, a quick ratio of 1.85 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $901.06, a P/E ratio of 212.44, a P/E/G ratio of 1.38 and a beta of 1.46. Amphastar Pharmaceuticals has a 12-month low of $13.15 and a 12-month high of $20.45.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.03. The business had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The business’s revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.01 earnings per share. equities analysts predict that Amphastar Pharmaceuticals will post 0.63 EPS for the current year.

In other news, Director Richard K. Prins sold 16,598 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $19.90, for a total value of $330,300.20. Following the sale, the director now directly owns 45,442 shares of the company’s stock, valued at $904,295.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jason B. Shandell sold 20,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total value of $388,600.00. Following the completion of the sale, the insider now directly owns 251,372 shares in the company, valued at $4,884,157.96. The disclosure for this sale can be found here. Insiders sold 84,387 shares of company stock valued at $1,659,763 over the last 90 days. Company insiders own 11.10% of the company’s stock.

Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $350,000. Millennium Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 1,746.9% in the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after acquiring an additional 277,771 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $197,000. Stone Ridge Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $214,000. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth approximately $229,000. 44.82% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/23/amphastar-pharmaceuticals-amph-rating-reiterated-by-wells-fargo.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.